Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

SyntheticMR AB: New Multicenter Study Demonstrates SyMRI's Potential to Transform Clinical Neuroimaging Workflows

SyntheticMR

SyntheticMR AB (publ) is proud to share the results of a newly published multicenter clinical study in the American Journal of Neuroradiology (AJNR), demonstrating the diagnostic equivalence-and potential advantages-of SyMRI® using the 3D-QALAS method compared to conventional 3D MRI in routine clinical neuroimaging. 

The peer-reviewed study, available here, evaluated a large and diverse patient population across multiple imaging centers. The findings confirmed that 3D synthetic MRI using SyMRI matched conventional MRI in sensitivity, specificity, and diagnostic accuracy. Notably, SyMRI received even higher ratings for image quality. 

"These results underscore the value of SyMRI in real-world clinical practice," said Johanna Norén, Acting CEO of SyntheticMR. "With diagnostic performance on par with conventional imaging-and with added benefits in workflow efficiency and quantitative imaging-SyMRI has the potential to enhance diagnostic confidence while streamlining MRI protocols." 

The study highlights SyMRI's ability-particularly in 3D-to deliver quantitative, multi-contrast images in a single, fast scan without compromising image quality, making it a strong candidate for advancing scalable and standardized neuroimaging practices. 

This clinical evidence further strengthens SyntheticMR's mission to redefine MRI efficiency, bringing the power of objective, quantitative imaging into routine clinical use. 

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.